Preferred Label : pomalidomide;

MeSH note : an immunomodulator with antineoplastic and angiogenesis inhibitor activity;

CISMeF synonym : CC-4047; actimid;

MeSH hyponym : CC 4047; CC4047;

Is substance : O;

UNII : D2UX06XLB5;

InChIKey : UVSMNLNDYGZFPF-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-zentiva
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
pomalidomide
pomalidomide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-accord
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
pomalidomide
pomalidomide
drugs, generic

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-teva
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drugs, generic
treatment outcome
pomalidomide
pomalidomide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-krka
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
pomalidomide
pomalidomide
drugs, generic

---
https://ansm.sante.fr/tableau-marr/pomalidomide
2025
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-viatris
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pomalidomide
pomalidomide
drugs, generic

---
https://www.has-sante.fr/jcms/p_3161433
2020
France
evaluation of the transparency committee
Imnovid
pomalidomide
pomalidomide
pomalidomide

---
https://www.has-sante.fr/jcms/p_3161436/fr/imnovid
2020
false
false
false
France
pomalidomide
pomalidomide
antineoplastic combined chemotherapy protocols
adult
multiple myeloma
dexamethasone
Bortezomib
treatment outcome
survival analysis
angiogenesis inhibitors
administration, oral
evaluation of the transparency committee
thalidomide
thalidomide

---
http://www.omedit-normandie.fr/media-files/6996/guide-imid-v200417-v2.pdf
2017
false
false
false
France
French
guideline
patient safety
pharmacy service, hospital
ambulatory care
thalidomide
drug prescriptions
pomalidomide
risk management
teratogens
pregnancy
multiple myeloma
immunologic factors
immunologic factors
immunologic factors
thalidomide
lenalidomide
pomalidomide
thalidomide
Lenalidomide

---
http://www.oncoprof.net/Generale2000/g11_AutresTraitements/Complements/g11_comp28.php
2017
false
false
false
France
French
drug information
pomalidomide
pomalidomide
thalidomide

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-immunomodulateurs-IMID-Thalidomide-Lenalidomide-Pomalidomide-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
thalidomide
Drug-Related side effects and adverse reactions
antineoplastic combined chemotherapy protocols
thalidomide
Drug-Related side effects and adverse reactions
administration, oral
antineoplastic agents
immunologic factors
lenalidomide
drug interactions
practice guideline
pomalidomide
pomalidomide
information dissemination
continuity of patient care
pregnancy
patient education as topic
thalidomide
Lenalidomide

---
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-10-fra.php#a22
2016
false
false
false
Canada
French
pharmacovigilance note
Reactivation of hepatitis B viral hepatitis (disorder)
pomalidomide
pomalidomide
pomalidomide
pomalidomide
thalidomide
thalidomide
thalidomide

---
http://www.e-cancer.fr/content/download/126023/1524677/file/Médicaments%20immunomodulateurs%20(imid).pdf
2015
false
false
false
France
French
guidelines for drug use
administration, oral
pomalidomide
lenalidomide
pomalidomide
thalidomide
thalidomide
thalidomide
antineoplastic agents
immunologic factors
continuity of patient care
information dissemination
hospital-physician relations
physician-patient relations
teratogens
contraception
pregnancy
drug interactions
practice guideline
Drug-Related side effects and adverse reactions
Lenalidomide

---
Summary Basis of Decision (SBD) for Pomalyst
Pomalidomide, 1 mg, 2 mg, 3 mg, and 4 mg, capsules, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?linkID=SBD00263
2014
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
treatment outcome
drug evaluation
risk assessment
pomalidomide
pomalidomide
pomalidomide
administration, oral
immunologic factors
immunologic factors
angiogenesis inhibitors
angiogenesis inhibitors
antineoplastic combined chemotherapy protocols
multiple myeloma
disease progression
clinical trials as topic
thalidomide
thalidomide
thalidomide

---
http://www.has-sante.fr/portail/jcms/c_1721768/fr/imnovid
http://www.has-sante.fr/portail/jcms/c_1721768/fr/imnovid-pomalidomide-immunomodulateur
2014
false
France
French
evaluation of the transparency committee
administration, oral
pomalidomide
pomalidomide
drug therapy, combination
treatment outcome
clinical trials, phase iii as topic
dexamethasone
multiple myeloma
disease-free survival
neoplasm recurrence, local
adult
thalidomide
guidelines for drug use

---
https://www.ema.europa.eu/medicines/human/EPAR/imnovid-previously-pomalidomide-celgene
2013
false
United Kingdom
English
French
pomalidomide
PVD Regimen
pomalidomide
pomalidomide
orphan drug production
drug approval
europe
treatment outcome
immunologic factors
immunologic factors
administration, oral
multiple myeloma
adult
drug therapy, combination
summary of product characteristics
package leaflet
drug evaluation
syndication feed
angiogenesis inhibitors
angiogenesis inhibitors
risk management
drug interactions
pregnancy
breast feeding
fertility
teratogens
survival analysis
clinical trials, phase iii as topic
drug evaluation, preclinical
thalidomide

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.